Skip to main content

Research Repository

Advanced Search

All Outputs (5)

Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer (2015)
Journal Article
Alsubhi, N., Middleton, F., Abdel-Fatah, T. M., Stephens, P., Doherty, R., Arora, A., …Madhusudan, S. (2016). Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. Molecular Oncology, 10(2), 213-223. https://doi.org/10.1016/j.molonc.2015.09.009

Radiation?induced DNA damage activates the DNA damage response (DDR). DDR up?regulation may predict radio?resistance and increase the risk of early local recurrence despite radiotherapy in early stage breast cancers. In 1755 early stage breast cancer... Read More about Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.

Lymphovascular invasion assessment and prognostic impact in melanoma and breast cancer (2015)
Journal Article
Thompson, N., Storr, S., Zhang, S., & Martin, S. (2015). Lymphovascular invasion assessment and prognostic impact in melanoma and breast cancer. Histology and Histopathology, 30(9), 1001-1009. https://doi.org/10.14670/HH-11-615

© 2015, Histology and Histopathology. All rights reserved. The presence of lymphovascular invasion is a recognised poor prognostic factor in a wide range of tumour types. Vascular invasion was historically identified through haematoxylin and eosin st... Read More about Lymphovascular invasion assessment and prognostic impact in melanoma and breast cancer.

FKBPL: a marker of good prognosis in breast cancer (2015)
Journal Article
Nelson, L., McKeen, H. D., Ellis, I., Rakha, E., Marshall, A., Mulrane, L., …Robson, T. (2015). FKBPL: a marker of good prognosis in breast cancer. Oncotarget, 6(14), 12209-12223. https://doi.org/10.18632/oncotarget.3528

FK506-binding protein-like (FKBPL) has established roles as an anti-tumor protein, with a therapeutic peptide based on this protein, ALM201, shortly entering phase I/II clinical trials. Here, we evaluated FKBPL’s prognostic ability in primary breast... Read More about FKBPL: a marker of good prognosis in breast cancer.